A limited federal hemp CBD and THC reimbursement program just launched, and anti-marijuana groups are already in court trying to block it. The fight is about access, federal authority and who gets to decide whether cannabinoids belong in patient care.
For all the noise around cannabis in Washington, this is one of the more interesting things the federal government has done in a while, and it happened with surprisingly little fanfare.
On April 1, a new federal program quietly began allowing certain participating care models to furnish up to $500 a year in eligible hemp-derived products for approved patients. The products can include CBD and a limited amount of THC, as long as they stay within the rules CMS laid out: non-inhalable, hemp-derived, no more than 0.3% delta-9 THC, no more than 3 milligrams per serving of tetrahydrocannabinols in orally administered form, no synthetic cannabinoids, and full compliance with state and local law.
And almost immediately, the backlash showed up.
On March 31, just before launch, Smart Approaches to Marijuana and nine other anti-marijuana organizations filed a lawsuit trying to stop the program before it got off the ground. Their complaint argues that CMS acted unlawfully, skipped required administrative steps and is venturing into dangerous territory by allowing access to non-FDA-approved cannabinoid products through a federal health program.
That clash is the real story here. Not just that the federal government opened a new hemp reimbursement pathway, but that the minute it did, prohibitionist groups went to court to shut it down.
To be clear, this is not broad Medicare coverage for everybody’s favorite gummies. It is narrower than that. The new Substance Access Beneficiary Engagement Incentive, or BEI, applies only inside certain CMS Innovation Center models: ACO REACH, the Enhancing Oncology Model, and the Long-term Enhance ACO Design Model, with the first two starting today and LEAD set to come online in 2027. Patients also cannot buy products at retail and submit receipts. CMS says the products must be furnished directly by a qualified physician affiliated with a participating organization, under an approved implementation plan and with required oversight.
Still, even with all those caveats, this is a meaningful federal shift.
For years, cannabinoid access at the federal level has lived in a weird place: politically useful, medically debated, heavily restricted and constantly hedged with bureaucratic language. This new program does not blow that up. But it does create something concrete. If a participating organization elects the BEI, gets CMS approval and follows the rules, it can furnish up to $500 annually per eligible beneficiary in approved hemp-derived products to help with symptom control. That is not a slogan. That is policy.
Marijuana Moment, which detailed the framework last month, noted that the plan allows a certain amount of THC, not just CBD, and that the agency tied the program to the Trump administration’s December executive order on marijuana rescheduling and hemp-derived cannabinoid access. The same report also made clear that this is a heavily structured system, not a federal free-for-all. Participating organizations need CMS approval, products must come from legally compliant and high-quality sources, and third-party testing is required for potency, contaminants and microbial hazards.
The anti-marijuana groups suing over the plan are trying to turn those limitations into grounds for killing it. In the lawsuit, SAM and the other plaintiffs argue that CMS never published a proper proposed rule for public comment, that the program conflicts with an earlier agency rule on cannabis products and that the initiative exceeds the agency’s legal authority. They also claim the move would affect Medicare recipients’ healthcare relationships without going through the right process.
Also read: Why You Shouldn’t Trust the Anti-Weed Lobby Smart Approaches to Marijuana
The politics of that are not subtle. Kevin Sabet, SAM’s CEO, used the lawsuit rollout to call hemp-derived products “snake oil” and argue that what CMS is allowing are not real medicines but loosely regulated products sold at gas stations and convenience stores. That line may play well in anti-cannabis circles, but it also conveniently ignores what CMS actually wrote: these products cannot just be pulled off a random retail shelf, they must be furnished through participating organizations, and they must meet specific production, testing and safety requirements.
That is part of why the lawsuit feels bigger than a narrow legal fight. What is really being tested here is whether the federal government is allowed to build even a tightly supervised, limited-access cannabinoid pathway without the old prohibition reflex kicking in.
And if you zoom out, the timing is impossible to ignore.
This launch lands while the federal government is still dealing with the aftermath of Trump’s December order directing the attorney general to move quickly on marijuana rescheduling, while CMS is revisiting cannabinoid policy in insurance-related settings, and while FDA and HHS are also moving through their own CBD compliance and enforcement discussions. None of that adds up to federal legalization. But it does suggest the government is looking for narrower, more controlled ways to integrate cannabinoids into the healthcare system without admitting the larger war has already been lost.
Also read: Anti-Cannabis Group SAM Says New York Weed Is Failing. The Data Says Otherwise.
There is also a deadline hanging over all of it. CMS says if federal hemp law changes later this year, including under the FY2026 Agriculture Appropriations Act, it will adjust the definition of eligible hemp products accordingly. That matters because the planned federal hemp restrictions expected in November could drastically shrink the kinds of products that remain legal. So even this newly launched program may have a countdown clock baked into it.
Which makes the whole thing feel even more like a snapshot of where cannabinoid policy sits in America right now: forward motion, but only in a narrow corridor. Access, but only under tight supervision. Federal recognition, but only with enough qualifiers to keep everyone pretending they are still in control.
Still, for patients inside the eligible models, and for the industry watching whether Washington can move even one inch without tripping over itself, today matters.
The federal government just started reimbursing certain hemp-derived CBD and THC products.
And the anti-weed groups did exactly what you’d expect: they ran to court.
